Anika Therapeutics, Inc.
US ˙ NasdaqGS ˙ US0352551081

Introduction

This page provides a comprehensive analysis of the known insider trading history of David Colleran. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David Colleran has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ANIK / Anika Therapeutics, Inc. EVP, General Counsel, Corp Sec 47,954
US:PODD / Insulet Corporation SVP, Secretary and GC 3,698
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David Colleran. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ANIK / Anika Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ANIK / Anika Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-05-11 ANIK Colleran David 1,500 21.3700 1,500 21.3700 32,055 268 32.1000 16,095 50.21
2022-03-14 ANIK Colleran David 1,500 26.6520 1,500 26.6520 39,978

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANIK / Anika Therapeutics, Inc. Insider Trades
Insider Sales ANIK / Anika Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ANIK / Anika Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANIK / Anika Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David Colleran as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-18 2025-03-17 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -1,893 47,954 -3.80 15.91 -30,118 762,948
2025-03-18 2025-03-17 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 6,448 49,847 14.86
2025-03-13 2025-03-11 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -2,250 43,399 -4.93 16.79 -37,778 728,669
2025-03-13 2025-03-11 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 7,663 45,649 20.17
2025-03-11 2025-03-10 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -1,604 37,986 -4.05 16.62 -26,658 631,327
2025-03-11 2025-03-10 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 5,465 39,590 16.01
2024-03-12 2024-03-11 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -2,250 32,995 -6.38 25.79 -58,028 850,941
2024-03-12 2024-03-11 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 7,662 35,245 27.78
2024-03-12 2024-03-11 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -1,605 27,583 -5.50 25.42 -40,799 701,160
2024-03-12 2024-03-11 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 5,465 29,188 23.04
2024-03-12 2024-03-11 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -1,081 23,723 -4.36 25.42 -27,479 603,039
2024-03-12 2024-03-11 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 3,682 24,804 17.43
2023-03-14 2023-03-10 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -2,250 20,288 -9.98 26.10 -58,725 529,517
2023-03-14 2023-03-10 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 7,663 22,538 51.52
2023-03-10 2023-03-09 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -1,081 14,875 -6.77 26.91 -29,090 400,286
2023-03-10 2023-03-09 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 3,683 15,956 30.01
2023-03-07 2023-03-04 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -734 12,273 -5.64 31.59 -23,187 387,704
2023-03-07 2023-03-04 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 2,500 13,007 23.79
2022-05-12 2022-05-11 4 ANIK Anika Therapeutics, Inc.
Common Stock
P - Purchase 1,500 9,867 17.93 21.37 32,055 210,858
2022-03-16 2022-03-14 4 ANIK Anika Therapeutics, Inc.
Common Stock
P - Purchase 1,500 8,367 21.84 26.65 39,978 222,997
2022-03-15 2022-03-11 4 ANIK Anika Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 35,864 35,864
2022-03-15 2022-03-11 4 ANIK Anika Therapeutics, Inc.
Restricted Stock Unit
A - Award 22,988 22,988
2022-03-11 2022-03-09 4 ANIK Anika Therapeutics, Inc.
Restricted Stock Unit
M - Exercise -3,682 7,365 -33.33
2022-03-11 2022-03-09 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -1,081 6,867 -13.60 26.22 -28,344 180,053
2022-03-11 2022-03-09 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 3,682 7,948 86.31
2022-03-07 2022-03-04 4 ANIK Anika Therapeutics, Inc.
Restricted Stock Unit
M - Exercise -2,500 2,500 -50.00
2022-03-07 2022-03-04 4 ANIK Anika Therapeutics, Inc.
Common Stock
F - Taxes -734 4,266 -14.68 31.06 -22,798 132,502
2022-03-07 2022-03-04 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 2,500 5,000 100.00
2021-03-11 2021-03-09 4 ANIK Anika Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 27,681 27,681
2021-03-11 2021-03-09 4 ANIK Anika Therapeutics, Inc.
Restricted Stock Unit
A - Award 11,047 11,047
2021-03-08 2021-03-04 4 ANIK Anika Therapeutics, Inc.
Restricted Stock Unit
M - Exercise -2,500 5,000 -33.33
2021-03-08 2021-03-04 4 ANIK Anika Therapeutics, Inc.
Common Stock
M - Exercise 2,500 2,500
2020-03-06 2020-03-04 4 ANIK Anika Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 35,000 35,000
2020-03-06 2020-03-04 4 ANIK Anika Therapeutics, Inc.
Restricted Stock Unit
A - Award 7,500 7,500
2019-04-04 2019-04-02 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
M - Exercise -7,395 3,698 -66.66
2019-04-04 2019-04-02 4 PODD INSULET CORP
Common Stock
S - Sale X -7,395 30,433 -19.55 94.89 -701,712 2,887,787
2019-04-04 2019-04-02 4 PODD INSULET CORP
Common Stock
M - Exercise X 7,395 37,828 24.30 30.98 229,097 1,171,911
2019-03-05 2019-03-01 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
M - Exercise -1,748 5,247 -24.99
2019-03-05 2019-03-01 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
M - Exercise -1,422 5,686 -20.01
2019-03-05 2019-03-01 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
M - Exercise -1,166 5,831 -16.66
2019-03-05 2019-03-01 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
M - Exercise -16,639 11,093 -60.00
2019-03-05 2019-03-01 4 PODD INSULET CORP
Common Stock
S - Sale -20,975 30,433 -40.80 94.65 -1,985,359 2,880,593
2019-03-05 2019-03-01 4 PODD INSULET CORP
Common Stock
M - Exercise 1,748 51,408 3.52 74.50 130,226 3,829,896
2019-03-05 2019-03-01 4 PODD INSULET CORP
Common Stock
M - Exercise 1,422 49,660 2.95 46.22 65,725 2,295,285
2019-03-05 2019-03-01 4 PODD INSULET CORP
Common Stock
M - Exercise 1,166 48,238 2.48 29.26 34,117 1,411,444
2019-03-05 2019-03-01 4 PODD INSULET CORP
Common Stock
M - Exercise 16,639 47,072 54.67 30.98 515,476 1,458,291
2019-02-26 2019-02-24 4 PODD INSULET CORP
Common Stock
F - Taxes -3,107 30,433 -9.26 87.60 -272,173 2,665,931
2019-02-26 2019-02-22 4 PODD INSULET CORP
Common Stock
F - Taxes -641 33,540 -1.88 87.60 -56,152 2,938,104
2019-02-19 2019-02-14 4 PODD INSULET CORP
Common Stock
F - Taxes -264 34,181 -0.77 84.83 -22,395 2,899,574
2019-02-06 2019-02-05 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
M - Exercise -6,834 6,997 -49.41
2019-02-06 2019-02-05 4 PODD INSULET CORP
Common Stock
S - Sale X -6,834 34,133 -16.68 80.72 -551,640 2,755,216
2019-02-06 2019-02-05 4 PODD INSULET CORP
Common Stock
M - Exercise X 6,834 40,967 20.02 29.26 199,963 1,198,694
2019-02-01 2019-01-31 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
M - Exercise -4,826 13,831 -25.87
2019-02-01 2019-01-31 4 PODD INSULET CORP
Common Stock
S - Sale X -4,826 34,133 -12.39 80.00 -386,080 2,730,640
2019-02-01 2019-01-31 4 PODD INSULET CORP
Common Stock
M - Exercise X 4,826 38,959 14.14 29.26 141,209 1,139,940
2018-11-15 2018-11-14 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
M - Exercise -4,264 7,108 -37.50
2018-11-15 2018-11-14 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
M - Exercise -1,849 27,732 -6.25
2018-11-15 2018-11-14 4 PODD INSULET CORP
Common Stock
S - Sale X -6,113 34,042 -15.22 80.41 -491,546 2,737,317
2018-11-15 2018-11-14 4 PODD INSULET CORP
Common Stock
M - Exercise X 4,264 40,155 11.88 46.22 197,082 1,855,964
2018-11-15 2018-11-14 4 PODD INSULET CORP
Common Stock
M - Exercise X 1,849 35,891 5.43 30.98 57,282 1,111,903
2018-07-03 2018-06-29 4 PODD INSULET CORP
Common Stock
F - Taxes -3,205 34,042 -8.60 85.70 -274,668 2,917,399
2018-05-16 2018-05-15 4 PODD INSULET CORP
Common Stock
S - Sale X -4,956 37,139 -11.77 86.24 -427,405 3,202,867
2018-02-27 2018-02-24 4 PODD INSULET CORP
Common Stock
F - Taxes -671 42,095 -1.57 75.55 -50,694 3,180,277
2018-02-27 2018-02-24 4 PODD INSULET CORP
Common Stock
F - Taxes -1,759 42,766 -3.95 75.55 -132,892 3,230,971
2018-02-26 2018-02-22 4 PODD INSULET CORP
Common Stock
F - Taxes -470 44,525 -1.04 80.46 -37,816 3,582,482
2018-02-15 2018-02-14 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
A - Award 6,995 6,995
2018-02-15 2018-02-14 4 PODD INSULET CORP
Common Stock
A - Award 2,685 44,995 6.35
2018-02-15 2018-02-13 4 PODD INSULET CORP
Common Stock
A - Award 11,962 42,310 39.42
2017-02-24 2017-02-22 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
A - Award 11,372 11,372
2017-02-24 2017-02-22 4 PODD INSULET CORP
Common Stock
A - Award 4,327 30,442 16.57
2016-06-30 2016-06-29 4 PODD INSULET CORP
Common Stock
F - Taxes -2,347 26,115 -8.25 29.71 -69,729 775,877
2016-02-26 2016-02-24 4 PODD INSULET CORP
Employee Stock Option (Right to Buy)
A - Award 18,657 18,657
2016-02-26 2016-02-24 4 PODD INSULET CORP
Common Stock
A - Award 6,835 28,462 31.60
2015-07-20 3 PODD INSULET CORP
Common Stock
43,254
2015-07-20 3 PODD INSULET CORP
Common Stock
43,254
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)